Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9770921 | PMC |
| http://dx.doi.org/10.1111/jth.14860 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Longitudinal bleeding assessment in von Willebrand disease utilizing an interim bleeding score.
J Thromb Haemost
October 2022
Department of Medicine, Queen's University, Kingston, Ontario, Canada.
Background: Assessment of bleeding phenotype is critically important in the diagnosis of von Willebrand disease (VWD). Despite advances in bleeding assessment tools (BATs), standardized tools to evaluate bleeding following diagnosis (interim bleeding) are lacking.
Objectives: We assessed the clinical utility of an interim bleeding protocol in a multicenter, international study involving patients with VWD.
COVID-19 Associated Hemophagocytic Lymphohistiocytosis and Coagulopathy: Targeting the Duumvirate.
Indian Pediatr
September 2020
Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Context: Preliminary data on coexistence of secondary hemophagocytic lymphohistiocytosis syndrome (HLH) and disseminated intravascular coagulation (DIC) in critically ill children with novel coronavirus disease (COVID-19) are emerging. Herein, we summarize the available literature and fill-in the gaps in this regard.
Evidence Acquisition: We have performed a literature search for articles in PubMed, EMBASE and Google Scholar databases till May 12, 2020, with following keywords: "COVID-19", "SARS-CoV-2", "HLH", "HScore", "coagulopathy", "D-dimer", "cytokine storm", "children" and "pediatrics" with interposition of Boolean operator "AND".
Anticoagulation Options for Coronavirus Disease 2019 (COVID-19)-Induced Coagulopathy.
Cureus
May 2020
Internal Medicine, University of Connecticut Health Center, Farmington, USA.
As the coronavirus disease 2019 (COVID-19) pandemic is evolving, coagulopathy induced by the disease and its severe complications are raising concerns in the medical community. Because coagulopathy caused by COVID-19 has been difficult to control, it is important to have a better understanding of what therapies have been studied thus far and what therapies have demonstrated better outcomes for hospitalized patients. This review is focused on literature, research, and expert clinical judgments published in 2020 with a few references to articles published earlier.
View Article and Find Full Text PDFISTH interim guidance on recognition and management of coagulopathy in COVID-19.
J Thromb Haemost
May 2020
Department of Emergency and Disaster Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
ISTH interim guidance on recognition and management of coagulopathy in COVID-19: A comment.
J Thromb Haemost
August 2020
Department of Surgery, University of Colorado Denver, Aurora, CO, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!